Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
Avatar

2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimize Toxicity? Is Cytarabine Still the SoC? Are Novel Agents Promising?

By 7th Eurasian Hematology Oncology Summit FEATURING Moshe Mittelman
By 7th Eurasian Hematology Oncology Summit FEATURING Moshe Mittelman
0 views
December 11, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
MDS and MPN
15:05
7th Eurasian Hematology Oncology Summit

2020 Updates on MDS: Is Deferasirox Beneficial for EFS? Can We Achie…

Feat. G. Garcia-Manero
18:36
7th Eurasian Hematology Oncology Summit

2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimi…

Feat. M. Mittelman
11:32
7th Eurasian Hematology Oncology Summit

2020 Updates on MDS: Role of Prognostic Models, Cytogenetics, IPSS, …

Feat. G. Garcia-Manero
26:20
7th Eurasian Hematology Oncology Summit

2020 Update on MPNs: What Is the Risk Adapted Management in PV? Is R…

Feat. T. Mughal